
3 Ports and Logistics Company, Drug Ingredients Maker and Naval Shipbuilder Stocks With a Strong Future Roadmap: Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders
Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders: ROE of 11.7% to 26.5% and FY22 to FY26 revenue CAGR of 9.2% to 23.2%. Prices as of 17 Nov 2026.
Updated: 18 Nov 2026 • 3:37 pm
Posted by:

Quick Answer
The three port, drug ingredient and warship stocks to watch are Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders. Their return on equity ranges from 11.7% to 26.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 23.2%. Mazagon Dock Shipbuilders leads on both return on equity at 26.5% and revenue growth at 23.2% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Port, drug ingredient and warship stocks give investors a way to track businesses that sit close to everyday demand in India. Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders cover a ports and logistics company, a drug ingredients maker and a naval shipbuilder.
This list covers three port, drug ingredient and warship stocks with complete current figures: Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Port, Drug Ingredient and Warship Stocks?
Port, drug ingredient and warship stocks are listed companies that run ports, terminals and logistics services across India, make active drug ingredients and finished medicines, and build warships and submarines for the navy. Their earnings depend on cargo volumes, drug orders and defence orders.
Port, Drug Ingredient and Warship Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Adani Ports and SEZ | 1,917 | 404,621 | 30.8 | 31.5 | 13.3 | 0.66 |
| Granules India | 815.5 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
| Mazagon Dock Shipbuilders | 1,847 | 82,854 | 29.0 | 48.1 | 26.5 | 0.05 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing port, drug ingredient and warship stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in port, drug ingredient and warship stocks can use the coming numbers to test whether growth is holding.
Why Do Port, Drug Ingredient and Warship Stocks Have a Strong Roadmap in India?
Port, drug ingredient and warship stocks have a strong roadmap in India because rising cargo volumes, steady outsourcing of drug making and large naval building plans keep widening the market for these companies.
- Ports. More trade moves through Indian terminals.
- Drug ingredients. Pharma firms source from reliable plants.
- Naval shipbuilding. The navy adds new vessels.
Why Adani Ports and SEZ Features Among These Port, Drug Ingredient and Warship Stocks
Among the port, drug ingredient and warship stocks on this list, Adani Ports and SEZ is India's largest private port operator, handling containers, bulk cargo and liquids at multiple ports, and it also offers logistics services and marine operations.
Revenue rose from Rs 19,343 crore in FY22 to Rs 40,854 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 4,953 crore in FY22 to Rs 12,782 crore in FY26, which works out to a compound annual growth rate of 26.7%.
In the June 2026 quarter, revenue grew 23.9% year on year to Rs 11,674 crore, while net profit rose 10.2% to Rs 3,650 crore. The company has a return on equity of 13.3%, a debt to equity ratio of 0.66 and a market capitalisation of Rs 404,621 crore. The stock trades at a P/E of 30.8, below the industry P/E of 31.5.
Roadmap: The company is adding port capacity, rail-linked logistics and international terminals as trade volumes rise. Integrated services from port to inland logistics improve customer stickiness.
What to watch: Follow cargo volumes, new terminals and logistics revenue.
Why Granules India Features Among These Port, Drug Ingredient and Warship Stocks
Among the cargo terminals, API maker and naval yard shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%.
Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Why Mazagon Dock Shipbuilders Features Among These Port, Drug Ingredient and Warship Stocks
Among the three companies on this list, Mazagon Dock Shipbuilders is a Mumbai-based defence shipyard that builds warships and submarines for the Indian Navy and also takes on ship repair and offshore work.
The company has a return on equity of 26.5%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 82,854 crore. The stock trades at a P/E of 29.0, below the industry P/E of 48.1.
Revenue rose from Rs 6,144 crore in FY22 to Rs 14,146 crore in FY26, a compound annual growth rate of 23.2%. Net profit grew from Rs 563 crore in FY22 to Rs 2,422 crore in FY26, which works out to a compound annual growth rate of 44.0%. In the June 2026 quarter, revenue grew 10.4% year on year to Rs 3,256 crore, while net profit rose 22.1% to Rs 512 crore.
Roadmap: The shipyard has a long order book of destroyers, frigates and submarines, and the multi-year build cycle gives revenue visibility. Capacity additions and a push towards indigenous submarine and warship programmes support its position as a core naval supplier.
What to watch: Monitor milestone-linked revenue on the big naval programmes and any fresh orders announced through the year.
Adani Ports and SEZ vs Granules India vs Mazagon Dock Shipbuilders on Key Financials
The table below sets the three port, drug ingredient and warship stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Adani Ports and SEZ | 19,343 | 40,854 | 20.6% | 12,782 | 31.3% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
| Mazagon Dock Shipbuilders | 6,144 | 14,146 | 23.2% | 2,422 | 17.1% |
Mazagon Dock Shipbuilders posts the highest return on equity in this group at 26.5%. Adani Ports and SEZ has the largest FY26 revenue at Rs 40,854 crore, and Mazagon Dock Shipbuilders shows the fastest revenue growth with a 23.2% compound annual rate. A useful habit with port, drug ingredient and warship stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several port operator, pharma ingredients and shipbuilding stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Adani Ports and SEZ | 9,422 | 11,674 | 23.9% |
| Granules India | 1,226 | 1,479 | 20.6% |
| Mazagon Dock Shipbuilders | 2,949 | 3,256 | 10.4% |
Key Risks to Check Before Investing in Port, Drug Ingredient and Warship Stocks
Every theme carries risks that deserve a check before any decision. For these port, drug ingredient and warship stocks, the main points are: Long-term cargo terminals, API maker and naval yard shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Cargo volumes. Freight and parcel volumes follow trade and consumption.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Order timing. Defence and space orders can shift between periods.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter port, drug ingredient and warship stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Port, Drug Ingredient and Warship Stocks
Port, drug ingredient and warship stocks work best when investors track growth, valuation and return on equity side by side. Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders each have a clear plan to grow. Based on the 17 November 2026 close, Adani Ports and SEZ trades at Rs 1,917, Granules India at Rs 815.5 and Mazagon Dock Shipbuilders at Rs 1,847. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these port, drug ingredient and warship stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track port, drug ingredient and warship stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are port, drug ingredient and warship stocks?
Ans. Port, drug ingredient and warship stocks are listed companies that run ports, terminals and logistics services across India, make active drug ingredients and finished medicines, and build warships and submarines for the navy. Their earnings depend on cargo volumes, drug orders and defence orders. This list looks at three of them, Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which port, drug ingredient and warship stocks are covered in this list?
Ans. This list covers Adani Ports and SEZ, Granules India and Mazagon Dock Shipbuilders. Based on the 17 November 2026 close, Adani Ports and SEZ traded at Rs 1,917, Granules India at Rs 815.5 and Mazagon Dock Shipbuilders at Rs 1,847. Their return on equity ranges from 11.7% to 26.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 23.2%.
Why do port, drug ingredient and warship stocks have a strong future roadmap in India?
Ans. Port, drug ingredient and warship stocks have a strong roadmap in India because rising cargo volumes, steady outsourcing of drug making and large naval building plans keep widening the market for these companies. The main drivers are as follows. Ports. More trade moves through Indian terminals. Drug ingredients. Pharma firms source from reliable plants. Naval shipbuilding. The navy adds new vessels. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Adani Ports and SEZ performed financially?
Ans. Revenue rose from Rs 19,343 crore in FY22 to Rs 40,854 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 4,953 crore in FY22 to Rs 12,782 crore in FY26, which works out to a compound annual growth rate of 26.7%. In the June 2026 quarter, revenue grew 23.9% year on year to Rs 11,674 crore, while net profit rose 10.2% to Rs 3,650 crore. The company has a return on equity of 13.3%, a debt to equity ratio of 0.66 and a market capitalisation of Rs 404,621 crore. The stock trades at a P/E of 30.8, below the industry P/E of 31.5. Looking ahead, the company is adding port capacity, rail-linked logistics and international terminals as trade volumes rise. Integrated services from port to inland logistics improve customer stickiness.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
How has Mazagon Dock Shipbuilders performed financially?
Ans. Revenue rose from Rs 6,144 crore in FY22 to Rs 14,146 crore in FY26, a compound annual growth rate of 23.2%. Net profit grew from Rs 563 crore in FY22 to Rs 2,422 crore in FY26, which works out to a compound annual growth rate of 44.0%. In the June 2026 quarter, revenue grew 10.4% year on year to Rs 3,256 crore, while net profit rose 22.1% to Rs 512 crore. The company has a return on equity of 26.5%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 82,854 crore. The stock trades at a P/E of 29.0, below the industry P/E of 48.1. Looking ahead, the shipyard has a long order book of destroyers, frigates and submarines, and the multi-year build cycle gives revenue visibility. Capacity additions and a push towards indigenous submarine and warship programmes support its position as a core naval supplier.
What risks should investors check before buying port, drug ingredient and warship stocks?
Ans. Investors should check a few risks before buying port, drug ingredient and warship stocks. Cargo volumes. Freight and parcel volumes follow trade and consumption. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Defence and space orders can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of port, drug ingredient and warship stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





